Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
IRMD's Cash-to-Debt is ranked higher than
80% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. IRMD: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
IRMD' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity-to-Asset 0.85
IRMD's Equity-to-Asset is ranked higher than
88% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. IRMD: 0.85 )
Ranked among companies with meaningful Equity-to-Asset only.
IRMD' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.74  Med: 0.87 Max: 0.91
Current: 0.85
0.74
0.91
Interest Coverage No Debt
IRMD's Interest Coverage is ranked higher than
81% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 73.23 vs. IRMD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
IRMD' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 5
Altman Z-Score: 14.03
Beneish M-Score: -3.09
WACC vs ROIC
11.14%
38.85%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 17.20
IRMD's Operating Margin % is ranked higher than
94% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.45 vs. IRMD: 17.20 )
Ranked among companies with meaningful Operating Margin % only.
IRMD' s Operating Margin % Range Over the Past 10 Years
Min: 17.2  Med: 24.58 Max: 36.44
Current: 17.2
17.2
36.44
Net Margin % 11.60
IRMD's Net Margin % is ranked higher than
88% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. IRMD: 11.60 )
Ranked among companies with meaningful Net Margin % only.
IRMD' s Net Margin % Range Over the Past 10 Years
Min: 11.6  Med: 17.08 Max: 23.83
Current: 11.6
11.6
23.83
ROE % 9.15
IRMD's ROE % is ranked higher than
83% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. IRMD: 9.15 )
Ranked among companies with meaningful ROE % only.
IRMD' s ROE % Range Over the Past 10 Years
Min: 9.15  Med: 28.51 Max: 44.82
Current: 9.15
9.15
44.82
ROA % 7.88
IRMD's ROA % is ranked higher than
91% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.49 vs. IRMD: 7.88 )
Ranked among companies with meaningful ROA % only.
IRMD' s ROA % Range Over the Past 10 Years
Min: 7.88  Med: 19.92 Max: 30.89
Current: 7.88
7.88
30.89
ROC (Joel Greenblatt) % 60.20
IRMD's ROC (Joel Greenblatt) % is ranked higher than
93% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 6.15 vs. IRMD: 60.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IRMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 60.2  Med: 157.55 Max: 276.75
Current: 60.2
60.2
276.75
3-Year Revenue Growth Rate 27.30
IRMD's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. IRMD: 27.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IRMD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 27.3  Med: 33.9 Max: 40.5
Current: 27.3
27.3
40.5
3-Year EBITDA Growth Rate 40.00
IRMD's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 6.30 vs. IRMD: 40.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IRMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 40  Med: 56.45 Max: 72.9
Current: 40
40
72.9
3-Year EPS without NRI Growth Rate 39.70
IRMD's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. IRMD: 39.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IRMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 39.7  Med: 57.85 Max: 76
Current: 39.7
39.7
76
» IRMD's 30-Y Financials

Financials (Next Earnings Date: 2017-10-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

IRMD Guru Trades in Q3 2016

Jim Simons 45,900 sh (New)
» More
Q4 2016

IRMD Guru Trades in Q4 2016

Jim Simons 26,300 sh (-42.70%)
» More
Q1 2017

IRMD Guru Trades in Q1 2017

Jim Simons 18,618 sh (-29.21%)
» More
Q2 2017

IRMD Guru Trades in Q2 2017

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:IRMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3841
Compare:NAS:IRIX, TSXV:PHM, NAS:NVTR, NAS:SPAN, NAS:VIVE, NAS:APEN, NAS:MSON, NAS:DRAD, NAS:ACRX, NAS:CGNT, NAS:SRTS, ASX:VTI, NAS:SPNE, NAS:OBLN, ASX:AXP, NAS:EYES, TSXV:HTL, OTCPK:BTCY, AMEX:ELMD, NAS:FONR » details
Headquarter Location:USA
iRadimed Corp develops, manufactures, markets and distributes Magnetic Resonance Imaging compatible products to acute care facilities and outpatient imaging centers, both in the United States and internationally.

iRadimed Corp was incorporated in Oklahoma in July 1992 and reincorporated in Delaware in April 2014. The Company develops, manufacture, market and distribute Magnetic Resonance Imaging ("MRI") compatible products. It is a sole provider of non-magnetic intravenous ("IV") infusion pump systems. Its mRidium MRI compatible IV infusion pump system uses a patented non-magnetic ultrasonic motor and other uniquely-designed non-ferrous parts that enable accurate, safe and dependable fluid delivery to patients undergoing an MR procedure. The Company operates in one reportable segment which is the development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures. In the U.S., the company sell its products through its direct sales force and outside of the U.S. through distributors who resell its products to end users. Its products includes MRidium 3860+ MRI IV PUMP, MRidium 3865 Remote Control, MRidium 3861 Sidcar, DERS (option) Dose Error Reduction System, SpO2 (option) Monitoring System, iMagox 2460 MRI SpO2 Monitor and iMagox 2465 Remote Control. The Company assemble its products in Winter Springs, Florida, from components and sub-assemblies purchased from outside suppliers. It have two alternate suppliers of its IV sets. The first is its own in-house IV set manufacturing capability, and the second is an OEM located in central Florida. Bayer Radiology, formerly MEDRAD, Inc. is a competitor of the company in the MRI compatible IV infusion pump market. Its medical device products are subject to extensive, complex and increasing oversight and regulation by the U.S. Food & Drug Administration ("FDA"), and other domestic and foreign governmental authorities.

Top Ranked Articles about iRadimed Corp

IRADIMED CORPORATION to Hold 2017 Second Quarter Financial Results Conference Call on July 28th
IRADIMED CORPORATION to Hold 2017 First Quarter Financial Results Conference Call on April 28th
IRADIMED Names John McCreery Chief Operating Officer

WINTER SPRINGS, Fla., March 30, 2017 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ:IRMD), today announced that John McCreery has been appointed Chief Operating Officer, a new position within the Company. Mr. McCreery will have primary responsibility over the regulatory, manufacturing and engineering departments of the Company.
Mr. McCreery, 62, is currently a tenured professor in operations and innovation at North Carolina State University’s College of Management. At NC State, he works with a wide variety of organizations – from start-ups to multinational firms – in operational excellence, innovation management, and leadership development initiatives. He has also served as Director of a cross-continent US-Europe-China graduate program in global innovation management. Prior to joining NC State, Mr. McCreery held roles in engineering, manufacturing, IT systems consulting, and company leadership, including Chief Operating Officer at Invivo Research. He received his undergraduate degree in Biomedical Engineering, with Honors, from Case Western Reserve University, an MBA from the University of Michigan, and a Ph.D. in operations management from Ohio State University. “John is a trusted leader and we are excited to have him join us as Chief Operating Officer. He brings deep knowledge and experience in the areas of regulatory affairs, manufacturing and engineering. We look forward to his arrival and leadership. Additionally, with John in place, I will be able to dedicate more time focusing on sales initiatives and new product development,” said Roger Susi, President and Chief Executive Officer of the Company.  About IRADIMED CORPORATION IRADIMED CORPORATION is a leader in the development of MRI compatible medical devices. We are the only known provider of non-magnetic intravenous (IV) infusion pump systems that are specifically designed to be safe for use during magnetic resonance imaging (MRI) procedures. We were the first to develop an infusion delivery system that largely eliminates many of the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency (RF) interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, uniquely-designed non-ferrous parts and other special features in order to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated in order to remain immobile during an MRI scan. Our 3880 MRI compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features in order to safely and accurately monitor a patient’s vital signs during various MRI procedures. The IRADIMED 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room, including in very close proximity to the MRI scanner bore. The IRADIMED 3880 has a compact, lightweight design allowing it to travel with the patient from their critical care unit, to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the IRADIMED 3880 include: wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; non-invasive blood pressure; patient temperature, and; optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The IRADIMED 3880 MRI compatible patient vital signs monitoring system has an easy-to-use design and allows for the effective communication of patient vital signs information to clinicians. Our 3880 MRI compatible patient vital signs monitoring system is currently available to international customers. Once we receive FDA 510(k) clearance, the 3880 will be available to U.S. customers. We currently anticipate commencing marketing the 3880 to U.S. customers in the third quarter of 2017. For more information please visit www.iradimed.com.
Media Contact:
Chris Scott
Chief Financial Officer
IRADIMED CORPORATION
(407) 677-8022
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 42.28
IRMD's PE Ratio is ranked higher than
65% of the 179 Companies
in the Global Medical Devices industry.

( Industry Median: 30.71 vs. IRMD: 42.28 )
Ranked among companies with meaningful PE Ratio only.
IRMD' s PE Ratio Range Over the Past 10 Years
Min: 13.33  Med: 35.84 Max: 516.67
Current: 42.28
13.33
516.67
Forward PE Ratio 84.75
IRMD's Forward PE Ratio is ranked lower than
94% of the 49 Companies
in the Global Medical Devices industry.

( Industry Median: 25.64 vs. IRMD: 84.75 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 42.28
IRMD's PE Ratio without NRI is ranked higher than
66% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 31.10 vs. IRMD: 42.28 )
Ranked among companies with meaningful PE Ratio without NRI only.
IRMD' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.33  Med: 35.84 Max: 516.67
Current: 42.28
13.33
516.67
PB Ratio 3.43
IRMD's PB Ratio is ranked higher than
51% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. IRMD: 3.43 )
Ranked among companies with meaningful PB Ratio only.
IRMD' s PB Ratio Range Over the Past 10 Years
Min: 2.75  Med: 6.56 Max: 12.56
Current: 3.43
2.75
12.56
PS Ratio 4.81
IRMD's PS Ratio is ranked lower than
52% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.32 vs. IRMD: 4.81 )
Ranked among companies with meaningful PS Ratio only.
IRMD' s PS Ratio Range Over the Past 10 Years
Min: 3.05  Med: 6.64 Max: 14.65
Current: 4.81
3.05
14.65
Price-to-Free-Cash-Flow 25.24
IRMD's Price-to-Free-Cash-Flow is ranked higher than
76% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 32.13 vs. IRMD: 25.24 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
IRMD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.52  Med: 29.06 Max: 120.37
Current: 25.24
12.52
120.37
Price-to-Operating-Cash-Flow 20.92
IRMD's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 19.50 vs. IRMD: 20.92 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IRMD' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.51  Med: 26.35 Max: 100.54
Current: 20.92
10.51
100.54
EV-to-EBIT 19.96
IRMD's EV-to-EBIT is ranked higher than
87% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 24.67 vs. IRMD: 19.96 )
Ranked among companies with meaningful EV-to-EBIT only.
IRMD' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.6  Med: 18.1 Max: 54.1
Current: 19.96
6.6
54.1
EV-to-EBITDA 18.52
IRMD's EV-to-EBITDA is ranked higher than
81% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 17.99 vs. IRMD: 18.52 )
Ranked among companies with meaningful EV-to-EBITDA only.
IRMD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.4  Med: 17.25 Max: 51.5
Current: 18.52
6.4
51.5
Current Ratio 9.08
IRMD's Current Ratio is ranked higher than
94% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.64 vs. IRMD: 9.08 )
Ranked among companies with meaningful Current Ratio only.
IRMD' s Current Ratio Range Over the Past 10 Years
Min: 3.42  Med: 9.32 Max: 11.76
Current: 9.08
3.42
11.76
Quick Ratio 7.91
IRMD's Quick Ratio is ranked higher than
95% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. IRMD: 7.91 )
Ranked among companies with meaningful Quick Ratio only.
IRMD' s Quick Ratio Range Over the Past 10 Years
Min: 2.77  Med: 8.14 Max: 10.93
Current: 7.91
2.77
10.93
Days Inventory 257.87
IRMD's Days Inventory is ranked lower than
73% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. IRMD: 257.87 )
Ranked among companies with meaningful Days Inventory only.
IRMD' s Days Inventory Range Over the Past 10 Years
Min: 140.91  Med: 185.82 Max: 257.87
Current: 257.87
140.91
257.87
Days Sales Outstanding 56.78
IRMD's Days Sales Outstanding is ranked higher than
80% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. IRMD: 56.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
IRMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 42.41  Med: 45.7 Max: 75.28
Current: 56.78
42.41
75.28
Days Payable 50.45
IRMD's Days Payable is ranked lower than
52% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 54.45 vs. IRMD: 50.45 )
Ranked among companies with meaningful Days Payable only.
IRMD' s Days Payable Range Over the Past 10 Years
Min: 50.45  Med: 66.48 Max: 70.05
Current: 50.45
50.45
70.05

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.50
IRMD's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. IRMD: -7.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IRMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.7  Med: -8.6 Max: -7.5
Current: -7.5
-9.7
-7.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.87
IRMD's Price-to-Net-Cash is ranked higher than
81% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 15.73 vs. IRMD: 5.87 )
Ranked among companies with meaningful Price-to-Net-Cash only.
IRMD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.74  Med: 10.13 Max: 15.31
Current: 5.87
4.74
15.31
Price-to-Net-Current-Asset-Value 3.92
IRMD's Price-to-Net-Current-Asset-Value is ranked higher than
77% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 6.83 vs. IRMD: 3.92 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
IRMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.36  Med: 7.33 Max: 10.77
Current: 3.92
3.36
10.77
Price-to-Tangible-Book 3.54
IRMD's Price-to-Tangible-Book is ranked higher than
61% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 3.98 vs. IRMD: 3.54 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IRMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.03  Med: 7.02 Max: 10.26
Current: 3.54
3.03
10.26
Price-to-Median-PS-Value 0.73
IRMD's Price-to-Median-PS-Value is ranked higher than
85% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. IRMD: 0.73 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IRMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.54  Med: 1.11 Max: 1.89
Current: 0.73
0.54
1.89
Price-to-Graham-Number 2.58
IRMD's Price-to-Graham-Number is ranked higher than
60% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. IRMD: 2.58 )
Ranked among companies with meaningful Price-to-Graham-Number only.
IRMD' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.74  Med: 3.74 Max: 11.32
Current: 2.58
1.74
11.32
Earnings Yield (Greenblatt) % 5.02
IRMD's Earnings Yield (Greenblatt) % is ranked higher than
93% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. IRMD: 5.02 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IRMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.8  Med: 5.5 Max: 15.3
Current: 5.02
1.8
15.3

More Statistics

Revenue (TTM) (Mil) $24.35
EPS (TTM) $ 0.24
Beta1.49
Short Percentage of Float18.93%
52-Week Range $7.85 - 19.09
Shares Outstanding (Mil)10.58

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 23 26
EPS ($) 0.12 0.20
EPS without NRI ($) 0.12 0.20
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for IRMD

Headlines

Articles On GuruFocus.com
IRADIMED CORPORATION to Hold 2017 Second Quarter Financial Results Conference Call on July 28th Jul 17 2017 
IRADIMED CORPORATION to Hold 2017 First Quarter Financial Results Conference Call on April 28th Apr 20 2017 
IRADIMED Names John McCreery Chief Operating Officer Mar 30 2017 

More From Other Websites
Edited Transcript of IRMD earnings conference call or presentation 28-Jul-17 3:00pm GMT Aug 12 2017
Zacks.com featured highlights: Stoneridge, Synthetic Biologics, IRadimed Corporation, Syntel and AXT Aug 09 2017
5 Cheap Breakout Stocks Offering Strong Returns Aug 08 2017
Corporate News Blog - Cesca Therapeutics Announces Issuance of New Cellular Processing Patent Jul 31 2017
IRadimed posts 2Q profit Jul 28 2017
IRADIMED CORPORATION Announces Second Quarter 2017 Financial Results Jul 28 2017
IRADIMED CORPORATION to Hold 2017 Second Quarter Financial Results Conference Call on July 28th Jul 17 2017
IRadimed Corp.: Gathering momentum, can it sustain its performance? Jun 26 2017
ETFs with exposure to IRadimed Corp. : June 5, 2017 Jun 05 2017
ETFs with exposure to IRadimed Corp. : May 9, 2017 May 09 2017
IRadimed Corp. :IRMD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 8, 2017 May 08 2017
Edited Transcript of IRMD earnings conference call or presentation 28-Apr-17 3:00pm GMT May 02 2017
ETFs with exposure to IRadimed Corp. : April 28, 2017 Apr 28 2017
Investor Network: iRadimed Corp to Host Earnings Call Apr 28 2017
IRadimed reports 1Q loss Apr 28 2017
IRadimed Corp. :IRMD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)